Oncology

Five things for pharma marketers to know: Monday, December 5, 2016

Five things for pharma marketers to know: Monday, December 5, 2016

By

The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy

Five things for pharma marketers to know: Friday, December 2, 2016

Five things for pharma marketers to know: Friday, December 2, 2016

By

Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

By

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

By

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

By

"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

By

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

Five things for pharma marketers to know: Friday, October 21, 2016

Five things for pharma marketers to know: Friday, October 21, 2016

By

Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand

Kite Pharma, developing a CAR-T therapy, hires new comms lead

Kite Pharma, developing a CAR-T therapy, hires new comms lead

By

The company hired Christine Cassiano, who is charged with preparing the communications strategy for the drugmaker's experimental cancer therapy.

Pro ad report: All the data on journal spending in 1H 2016

Pro ad report: All the data on journal spending in 1H 2016

By

Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.

Five things for pharma marketers to know: Tuesday, October 11, 2016

Five things for pharma marketers to know: Tuesday, October 11, 2016

By

Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies

Five things for pharma marketers to know: Tuesday, October 4, 2016

Five things for pharma marketers to know: Tuesday, October 4, 2016

By

J&J insulin pumps are at risk of hacking; Merrimack CEO leaves and cuts workforce; Japanese scientists wins Nobel

Novartis sets out to debunk misconception that only smokers get lung cancer

Novartis sets out to debunk misconception that only smokers get lung cancer

By

Approximately 10% to 15% of lung cancer patients have never smoked and have developed the disease due to genetic alterations.

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

By

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Five things for pharma marketers to know: Tuesday, August 16, 2016

Five things for pharma marketers to know: Tuesday, August 16, 2016

By

OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children

5 Ways to Improve the Customer Experience for Oncologists

5 Ways to Improve the Customer Experience for Oncologists

One critical aspect of oncology drugmakers' business remains firmly rooted in the past. That's customer experience.

One year on: Inside Bayer's effort to get prostate cancer patients to speak up

One year on: Inside Bayer's effort to get prostate cancer patients to speak up

By

Bayer recently tapped Ken Griffey Sr. and Ken Griffey Jr. — the first father-son duo to be inducted into the Baseball Hall of Fame — as spokespeople.

Five things for pharma marketers to know: Thursday, August 11, 2016

Five things for pharma marketers to know: Thursday, August 11, 2016

By

Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana

Opdivo bet backfires, creates opening for Merck to pursue DTC

Opdivo bet backfires, creates opening for Merck to pursue DTC

By

A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.

Five things for pharma marketers to know: Monday, July 25, 2016

Five things for pharma marketers to know: Monday, July 25, 2016

By

Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting

As immuno-oncology therapies evolve, so will the marketing

As immuno-oncology therapies evolve, so will the marketing

By

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

By

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

By

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Five things for pharma marketers to know: Monday, July 18, 2016

Five things for pharma marketers to know: Monday, July 18, 2016

By

Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages

Cancer detection tool among projects chosen for Publicis90 initiative

Cancer detection tool among projects chosen for Publicis90 initiative

By

U.S. companies accounted for nearly a quarter of the startups funded to celebrate Publicis' 90th anniversary.

Five things for pharma marketers to know: Wednesday, June 29, 2016

Five things for pharma marketers to know: Wednesday, June 29, 2016

By

GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center

Dudnyk's Angelina Sciolla on Refreshing the Oncology Narrative

Dudnyk's Angelina Sciolla on Refreshing the Oncology Narrative

Think chess game rather than bare knuckle brawl.

Five things for pharma marketers to know: Tuesday, June 21, 2016

Five things for pharma marketers to know: Tuesday, June 21, 2016

By

Cancer docs push HPV vaccine; GSK says experimental lung combo trumps Symbicort; Google rolls out new symptom search feature

Five things for pharma marketers to know: Friday, June 10, 2016

Five things for pharma marketers to know: Friday, June 10, 2016

By

FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec

OPINION

Email Newsletters